 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at the April 2020 Virtual Investor Summit on Wednesday, April 22, 2020 at 10:30 AM ET. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Companys website outlooktherapeutics.com. 